The World’s First
- Multiomic. AI-Driven. Continuously Updating.
- Built by Genetrack Biolabs × Canada's Michael Smith Genome Sciences Centre.
- Backed by Genome Canada and Genome BC (GAPP).
Industry Lead
Research Lead
Funding Partner
Funding Partner
Cancer Doesn’t Stand Still. Neither Should Diagnostics.
Most cancer tests rely on fixed gene panels and produce a static, one-time report. But oncology science evolves continuously: new therapies, biomarkers, trials, and evidence.
A New Standard for Precision Oncology
Transforms cancer testing from a static report into a continuously updating, AI-driven clinical intelligence system.
We combine tumour–normal whole-exome sequencing, whole-transcriptome RNA profiling, and a longitudinal AI engine that continuously reanalyzes patient data, identifying new therapeutic opportunities as they emerge, while notifying clinicians and patients in real time.
This is precision oncology that evolves with every breakthrough.
What Makes GenTraceDx Different
Multiomic Depth (WES + RNA)
Go beyond panels. Capture rare mutations, fusions, structural variants, pathway signatures, and expression-level biology missed by conventional tests.
Agentic AI & Discovery Engine
Our platform monitors global evidence , FDA/EMA approvals, NCCN updates, biomarker studies, clinical trials, and automatically updates patient insights.
Clinically Deployable at Scale
Leveraging 26 years of manufacturing and clinical pipeline experience to readily deploy nationwide at scale across oncology clinics in the U.S. and Canada.
Static Reports Say “No Options.” Living Diagnostics Find Opportunities.
Static panel tests miss clinically significant opportunities.
GenTraceDx provides a Longitudinal Agentic AI Discovery Engine that ensures patients never miss a therapy because their test was out of date.
A gastric cancer patient who had exhausted eight years of therapy received “no actionable findings” from legacy panel tests.
Our matched tumour-normal WES+RNA analysis identified high CLDN18.2, uncovering zolbetuximab as a therapeutic option months before it reached standard clinical awareness.
Additional options emerged, and the same analysis guided a personalized neoantigen vaccine approved under Health Canada’s OLIP CTA.
This is what static diagnostics miss, and what GenTraceDx delivers.
Built by Canada’s Strongest Genomics Partnership
Industry Lead
- 26-Year Industry Leader in FDA/Health Canada regulated diagnostics and mass-scale kit manufacturing.
- Proven Digital Infrastructure: Proprietary Physician & Patient Portals currently powering secure clinical workflows for over 3 million patients and major retail chains including CVS and Walgreens.
- National Scale: Exclusive white-label designer and manufacturer for nationwide diagnostic kit programs across the U.S. and Canada.
- Full Compliance: CAP/CLIA/AABB GMP and ISO certified facilities.
Research Lead
- World-Renowned Cancer Genomics: A premier global institution and pioneer in clinical-grade matched WES + RNA analysis at scale.
- Developed GraphKB, the Nature-published architecture that unifies and standardizes fragmented global clinical evidence.
- Clinical Pipeline Excellence: CAP/CLIA/DAP accredited workflows that have sequenced thousands of advanced cancer patients.
- Elite Scientific Foundation: Built upon decades of peer-reviewed innovation and world-leading genomic research.
Built for Real-World Clinical Adoption
Backed by $6M in funding from Genome Canada, Genome BC, and Genetrack, GenTraceDx is launching a 500-patient national pilot across North America.
This pilot is designed to integrate GenTraceDx directly into oncology workflows nationwide, positioning the platform for immediate adoption following validation.
This pilot establishes our longitudinal, agentic AI discovery engine as a new standard for clinical care. By integrating matched WES+RNA analysis with our proprietary physician and patient portals, we are generating the evidence base for our planned 2027 North American commercial rollout.
Built for Clinicians, Researchers, Patients & Partners
Clinicians
Participate in a national clinical pilot for continuously updating precision oncology.
Researchers & Partners
Support clinical research and real-world evidence generation across academic and industry partnerships.
Patients & Families
Understand how living diagnostics evolve with your care journey.
Media & Investors
Access press materials, leadership profiles, and official resources.
